Cyclopharm Announces Immediate Technegas Rollout at University Hospitals
Key points
- Cyclopharm secures agreement with University Hospitals for Technegas installations
- Agreement covers immediate deployment across 11 clinical locations
- Strengthens Cyclopharm's presence in the US healthcare market
- Reflects confidence in Technegas's clinical utility and potential for growth
Full summary
Cyclopharm Limited (ASX: CYC) has entered into a significant agreement with University Hospitals (UH), Cleveland, Ohio, for the immediate installation of Technegas across 11 clinical locations. This agreement marks a major milestone in Cyclopharm's US expansion strategy, with all installations set to be completed within weeks. UH's decision to prepare all sites ahead of signing underscores its commitment to the rollout. The agreement not only deepens Cyclopharm's footprint in northern Ohio but also positions Technegas as a key tool in functional ventilation imaging, with potential applications in various respiratory conditions and interventional lung procedures. Cyclopharm's Managing Director and CEO, James McBrayer, highlighted the significance of this agreement, emphasizing the immediate, system-wide deployment as a testament to Technegas's recognized clinical value.
Summary generated by a large language model. Please interpret with care.